Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who prog...
Lyell Immunopharma Announces Participation in March Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, in Boston, Massachusetts; presentation at 9:10am Eastern TimeLeerink Annual Glob...
Kyntra Bio to Participate in Upcoming Investor Conferences SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation Date & Time: Thursday, February 26, 2026, 2:40-3:10 PM ET Location: Virtual Webcast: Leerink Global Healthcare ConferenceFormat: Corporate Presentation Date & Time: Wednesday, March 11, 2026, 2:20-2:50 PM ETLocation: Miami, FL Webc...
A director at Prospect Capital Corp bought 942,800 shares at 2.917USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second-line settingThe pivotal single-arm trial, PiNACLE, evaluating ronde-cel in the third- or later-line setting is ongoing with BLA submission expected in 2027Site activation for both PiNACLE – H...
Prospect Capital Announces Financial Results for December 2025 NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended December 31, 2025. FINANCIAL RESULTS All amounts in $000’s exceptper share amounts (on weighted average basis for period numbers)Quarter EndedQuarter EndedQuarter Ended December 31, 2025September 30, 2025December 31, 2024 Net Investment Income (“NII”)$90,888$79,350$86,431NII per Common Share$0.19$0.17$0.20Interest as % of Total Investment Income8...
Prospect Capital Schedules Second Fiscal Quarter Earnings Release and Conference Call NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (the “Company” or “Prospect”) today announced it expects to file with the Securities and Exchange Commission its report on Form 10-Q containing results for the fiscal quarter ended December 31, 2025 and to issue its earnings press release on Monday, February 9, 2026, after the close of the markets. The Company will host a conference call on Tuesday, February 10, 2026 at 9:00 a.m. Eastern Time. The conference call dia...
TaskUs, Inc. (TASK - $11.11)AI Pivot Underway, We Think Up to the TASK; Mike Piccolo Initiating Coverage at OUTPERFORM with $15 Price Target. We are initiating coverage on TASK with an OUTPERFORM rating and a price target of $15 per share as we believe shares represent an attractive risk/reward opp
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.